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Abstract
Rationale Buspirone, a partial 5HT1A agonist and D2 and
D3 antagonist, has shown promising antiemetic efficacy
when given parenterally in animal models, but its efficacy
for the prevention of postoperative nausea and vomiting
(PONV) is unknown.
Objective To study the efficacy and dose-responsiveness of
intravenous buspirone for the prevention of PONV.
Methods A randomised, double-blind, placebo-controlled
study was performed in adults at moderate to high PONV
risk undergoing surgery with a general anaesthetic. Patients
were randomised to receive an intravenous dose of buspirone
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P. Kranke
Department of Anaesthesiology and Critical Care,
University Hospitals of Würzburg,
97080 Würzburg, Germany
K. D. Röhm
Department of Anaesthesiology and Intensive Care Medicine,
Klinikum Ludwigshafen,
67063 Ludwigshafen, Germany
P. Diemunsch
Department of Anaesthesiology and Intensive Care,
University Hospital of Hautepierre,
67000 Strasbourg, France
T. J. Gan
Department of Anesthesiology, Duke University Medical Center,
Durham, NC 27710, USA
C. C. Apfel
Department of Anesthesiology, UCSF Medical Center at Mt Zion,
San Francisco, CA 94115, USA
L. Eberhart
Department of Anaesthesiology and Intensive Care,
Philipps University Marburg,
35033 Marburg, Germany
H. S. Minkowitz
Department of Anesthesiology,
Memorial Hermann-Memorial City Medical Center,
Houston, TX 77024, USA
J. Wallenborn
Department of Anaesthesiology and Intensive Care Medicine,
University of Leipzig,
04103 Leipzig, Germany
D. Chassard
Service d’Anesthésie, Hôpital Mère Enfant,
69500 Bron, France
G. Lebuffe
Department of Anaesthesiology and Intensive Care,
Huriez Hospital, University Hospital of Lille,
59037 Lille, France
G. M. Fox
Acacia Pharma Ltd,
Cambridge CB22 7GG, UK
M. R. Tramèr (*)
Division of Anaesthesiology, Geneva University Hospitals,
Rue Gabrielle-Perret-Gentil 4,
1211 Geneva 14, Switzerland
e-mail: martin.tramer@hcuge.ch
Eur J Clin Pharmacol (2012) 68:1465–1472
DOI 10.1007/s00228-012-1284-8
(0.3, 1.0, 2.0, 3.0 mg) or placebo at the end of surgery. The
primary endpoint was the cumulative 24-h PONV incidence
(i.e. any nausea and/or vomiting). Vomiting included retching.
Nausea was defined as a score of ≥4 on an 11-point verbal
rating scale running from zero (no nausea) to ten (the worst
nausea imaginable).
Results A total of 257 patients received the study drug
and fulfilled the criteria for inclusion in the primary efficacy
and safety analyses. With placebo, the mean 24-h PONV
incidence was 49.0 % (90 % confidence interval [CI]
37.5–60.5 %). With buspirone, that incidence ranged from
a mean of 40.8 % (29.3–52.4 %) in the 1 mg arm to 58.0 %
(46.5–69.5 %) in the 0.3 mg arm (P>0.05 for all compar-
isons). There was no difference between placebo and bus-
pirone at any dose for any other efficacy endpoint, nor
in the number or severity of adverse events or any other
safety measures.
Conclusion We were unable to show that intravenous
single-dose buspirone, at the tested dose-range, was effec-
tive at preventing PONV in surgical adult patients. The
present study emphasises the difficulty in extrapolating from
animal models of emesis to clinical efficacy in PONV.
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Introduction
Postoperative nausea and vomiting (PONV) remain a sig-
nificant medical problem, despite the availability of numer-
ous anti-emetics [1]. Risk factors for PONV include female
sex, non-smoking status, prior history of PONV or motion
sickness, postoperative opioid usage, use of volatile anaes-
thetics and the type and duration of surgery [2].
Numerous mechanisms have been implicated in PONV,
most notably the release of serotonin from the gut wall and
activation of the chemoreceptor trigger zone in the brain.
Several types of receptors seem to be involved in PONV,
and these represent effective targets for drug therapies.
Among the most important are the dopaminergic (D2), se-
rotoninergic (5HT3) and neurokinin (NK1) receptors, and
the majority of effective antiemetics are active against one
or more of these receptors. Clinical and pre-clinical evi-
dence also suggests a possible role for 5HT1A and D3
receptors as effective antiemetics [3–5].
PONV is typically managed using a prophylactic multi-
modal approach, including the frequent use of combination
pharmacotherapy, especially in high-risk patients [6]. At the
present time, there is general agreement that effective pro-
phylaxis should involve the administration of one or more
antiemetic agent in patients estimated to be at moderate or
high risk of PONV [7].
Despite considerable improvement in the pharmacologi-
cal control of PONV during recent years, there remains a
significant need for new antiemetic agents. For example,
even with the use of prophylaxis, PONV still occurs fre-
quently and must then be treated, ideally with an agent
having a different mechanism of action from those used
for prevention [8]. Also, there is a particular requirement
for agents with good antinausea activity [9]. Finally, surgical
patients often receive strong opioids for pain control post-
operatively, and it is this group of analgesics that is likely to
provoke emetic symptoms. Thus, there is an ongoing need
for antiemetic drugs to control opioid-induced emesis.
Buspirone hydrochloride, an anxiolytic agent introduced
in the 1980s, is a 5HT1A partial agonist and D2 and D3
antagonist [10]. It has been considered to be a potential
antiemetic due to the importance of these pathways in nau-
sea and vomiting. Given subcutaneously, buspirone has
shown antiemetic efficacy in numerous animal models
[11–14]. However, oral buspirone was found to be ineffec-
tive against cisplatin-induced emesis in a human trial [15].
This lead to the hypothesis that the failure of oral buspirone
may result from its extensive first pass metabolism in the
liver to 1-pyrimidinylpiperazine (1-PP) [16], an α2-antago-
nist shown to have pro-emetic potential in the ferret. Paren-
teral administration of buspirone avoids such first-pass
metabolism. However, the antiemetic efficacy of parenteral
buspirone in humans remains unknown.
The study reported here was conducted to explore the
prophylactic antiemetic efficacy of different doses of intra-
venous buspirone in surgical patients. We hypothesised that
intravenous buspirone, in the dose range tested and in a
dose-dependent manner, would prevent PONV without in-
ducing unacceptable adverse effects.
Methods
Study participants
Adults who had given written, informed consent were en-
rolled if they were due to have an in-patient operation under
general anaesthesia (other than intra-thoracic, transplant or
central nerve system surgery) that was expected to last at
least 1 h and during which inhalational anaesthetics were to
be used as maintenance agents and if they had at least two of
four pre-specified risk factors for developing PONV: (1)
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female sex; (2) non-smoking status; (3) a prior history of
PONV or motion sickness; (4) the expectation of receiving
opioids for postoperative analgesia. Patients had to have
adequate haematological, renal and hepatic function (ala-
nine aminotransferase and aspartate aminotransferase lev-
els of<2.5×upper limit of normal [ULN]; bilirubin and
creatinine levels of<1.5×ULN; haemoglobin≥9.5 g dL-1;
white cell count range 4.0–11.0×109 L-1; platelet count
range 150–400×109 L-1) and were excluded if they were
expected to require postoperative ventilation or if they
had Parkinson’s disease, a clinically significant cardiac
arrhythmia or epilepsy.
Study design
This double-blind, placebo-controlled, parallel-group study
was conducted at 17 centres in France, Germany, Switzer-
land and the USA. Each centre obtained independent approval
from their institutional ethics committees and their national
drug safety agencies (Germany: Bundesinstitut für Arzneimit-
tel und Medizinprodukte; France: Agence française de sécur-
ité sanitaire des produits de santé; Switzerland: Swissmedic;
USA: Food and Drug Administration [FDA]).
Intravenous buspirone hydrochloride (strength
4.0 mg mL-1, diluted in phosphate buffered saline, pH 5.5)
and matching placebo (phosphate buffered saline, pH 5.5),
both manufactured specifically for the study, were supplied
to each site pharmacy by the sponsor. By means of an
interactive telephone- and internet-based randomisation ser-
vice, the site obtained a randomised treatment allocation for
each subject to one of five groups: 0.3, 1, 2 or 3 mg of
buspirone or placebo. The range of doses was determined at
the upper end by considering the tolerability profile of
intravenous buspirone in healthy volunteers and at the lower
end by extrapolation from efficacy data seen in ferrets, using
a conversion factor of 5.3 to take into account the species
difference in surface area to volume ratio, in line with FDA
guidance [17]. The randomisation was stratified by country
and by number of risk factors (2 vs. 3 or 4). An unblinded
pharmacist at each site, with no other study involvement,
made up a treatment syringe of equal volume (28 ml) contain-
ing placebo or the appropriate dose of buspirone for each
subject. Syringes were matching and were labelled with the
randomisation number only to ensure that allocation was
concealed and that the investigators, other study personnel
and subjects were all blinded as to treatment group.
Pre-medication and anaesthetic regimens were at the inves-
tigators’ discretion, except that total intravenous anaesthesia
with propofol, which may have antiemetic properties, was not
permitted, nor was it allowed to give any anti-emetic pre-
operatively. The study drug was administered by slow intra-
venous push over 1 min at the end of surgery, defined as up to
15 min before completion of wound closure.
Assessments
The primary endpoint of the study was the cumulative
incidence of PONV (i.e. vomiting or significant nausea) in
the 24-h period after the end of surgery. Vomiting included
retching. Significant nausea was defined as a score of ≥4 on
an 11-point verbal rating scale running from zero (no nausea
at all) to ten (the worst nausea imaginable). Patients were
asked prospectively by blinded dedicated research assistants
about nausea every 30 min after surgery up to and including
the 1-h mark and then again at 6 and 24 h. Any nausea
spontaneously reported by the patient was also recorded.
Secondary efficacy endpoints included the time to first
vomiting and the use of any antiemetic rescue medication,
which could be requested by the patient at any time. Further
evaluation was specified in the early postoperative period
(0–2 h) as well as at 2–6 h and 6–24 h postsurgery. Safety
was analyzed in terms of the nature and incidence of adverse
events and the change in Aldrete score between baseline and
1 h postoperatively. The Aldrete score is a validated instru-
ment for assessing recovery from anaesthesia which assigns
a score of 0–2 to each of five domains (activity, respiration,
circulation, consciousness and oxygen saturation), giving a
total score of up to 10 [18].
Although pharmacokinetics was not a primary aim of this
clinical dose-finding study, we evaluated pharmacokinetics
for a selection of patients in each study arm in order to
determine if there was any difference between the anaesthe-
tised individuals in this study and healthy volunteers. For
practical reasons, sampling was limited to five study sites.
Samples at time zero, 5 and 30 min, 1 and 4 h were selected
from three to five subjects per study arm for analysis. Data
were analyzed for concentration of buspirone and its major
metabolite, 1-PP.
The primary statistical test was a comparison of the
incidence of PONV between each treated group and the
placebo group using Pearson’s chi-square test with con-
tinuity correction, with a one-sided significance level of
0.1. A sample size of 50 evaluable patients per group
was calculated to give a power of 85 % to detect a
difference between the expected placebo PONV rate of
60 % and a target PONV rate of 35 % in the best active
treatment group.
Results
In total, 298 patients were screened and 281 were rand-
omised into the study (Fig. 1). Twenty-four patients did
not receive the study drug, mostly because their opera-
tion was cancelled or postponed (11 cases), the study
drug was unavailable (5 cases) or they withdrew consent
prior to surgery (5 cases). This left 257 patients who
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received the study drug and fulfilled the criteria for
inclusion in the primary safety and efficacy analyses.
Study arms were well balanced for age, sex, body mass
index and race (Table 1). The mean age of patients at enrol-
ment was 50.6 years, and 89.9 % were female.
There were no significant differences between study arms
in terms of past medical history, baseline physical examina-
tion, vital signs and type of operation. Hysterectomy oc-
curred in 22.6 % of patients, laparoscopic surgery other than
hysterectomy or cholecystectomy in 19.8 %, and breast
surgery in 14.4 %.
There were no significant differences between study arms
in terms of anaesthetic technique. All patients except one
received opioids, and 93 % received a volatile anaesthetic
(desflurane, isoflurane or sevoflurane). Among the few who
did not receive a volatile anaesthetic, two received total
intravenous anaesthesia with propofol and were therefore
protocol violators and subsequently excluded from the
N = 298
Patients screened
N = 17
Screening failures and
others not randomized
N = 281
Patients randomized
N = 24
Did not receive study drug
N = 257
Patients dosed
N = 51
Placebo
N = 50
Buspirone 0.3mg
N = 49
Buspirone 1mg
N = 52
Buspirone 2mg
N = 55
Buspirone 3mg
N = 50
Completed per-
protocol
N = 48
Completed per-
protocol
N = 49
Completed per-
protocol
N = 51
Completed per-
protocol
N = 54
Completed per-
protocol
N = 1
Major
violation
(antiemetic in
pre-med)
N = 2
Major
violation
(TIVA with
propofol)
N = 1
Major
violation
(TIVA with
propofol)
N = 1
Major
violation
(antiemetic in
pre-med)
Reasons:
Surgery postponed or cancelled (11)
Withdrew consent (5)
Study drug unavailable (5)
Protocol noncompliance (2)
Investigator judgement (1)
Fig. 1 Flowchart of study.
TIVA Total intravenous
anaesthesia with propofol
Table 1 Baseline demographics. There were no significant differences between groups
Demographic characteristics Placebo
(N051)
Buspirone 0.3 mg
(N050)
Buspirone 1 mg
(N049)
Buspirone 2 mg
(N052)
Buspirone 3 mg
(N055)
Age (years) 51.2 (20-76) 49.4 (19–86) 49.5 (21–85) 52.3 (25–86) 50.3 (25–78)
Body mass index (kg m-2) 27.1 (18.1–40.9) 26.9 (15.1–42.9) 26.8 (17.7–40.2) 26.7 (19.1–47.0) 26.9 (17.1–42.6)
Female 45 (88.2 %) 49 (98.0 %) 43 (87.8 %) 45 (86.5 %) 49 (89.1 %)
White/Caucasian 50 (98.0 %) 48 (96.0 %) 47 (95.9 %) 51 (98.1 %) 47 (85.5 %)
Data are presented as the mean with the range in parenthesis, or as the number with the percentage in parenthesis
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analysis. Thirty-nine patients (15 %) received nitrous oxide
and 43 (17 %) had their neuromuscular block reversed with
neostigmine. These patients were evenly distributed among
the groups. In terms of predefined risk factors, 45 patients
had two of the risk factors, 38 % had three and 17 % had
four.
Efficacy
In the placebo group, the mean 24-h incidence of PONV
was 49.0 % (90 % confidence interval [CI] 37.5–60.5 %).
There was a lower incidence of PONV among patients
receiving placebo who were prospectively identified as hav-
ing two risk factors than among those with three or four risk
factors (40.9 vs 59.9 %, respectively; odds ratio 0.46, 90 %
CI 0.28–0.74; P00.0081).
With buspirone, the mean 24-h incidence of PONV
ranged from 40.8 % (90 % CI 29.3–52.4 %) in the 1 mg
arm to 58.0 % (46.5–69.5 %) in the 0.3 mg arm. There was
no significant difference in the incidence of PONV between
placebo and any of the buspirone study arms (Table 2).
In the placebo group, the mean 24-h incidence of vomiting
alone and nausea alone was 27.5 and 43.1 %, respectively.
There was no significant difference in the incidence of vomit-
ing or nausea between patients receiving placebo and any of
those enrolled in the buspirone study arms (Table 2).
The median time to first episode of vomiting across the
study population was 3.8 h, with the shortest time in the
2 mg buspirone group (median 2.1 h) and longest time in the
placebo and 0.3 mg buspirone groups (median 4.9 h). There
was no significant difference between the groups. There was
also no difference between placebo and any active group in
terms of severity of nausea, measured as the area under the
curve, nor in the incidence of PONV, vomiting, including
retching, or nausea in each of the pre-specified time periods
after surgery.
Pharmacokinetics
The pharmacokinetic profile of intravenous buspirone in
anaesthetised patients was essentially similar to that seen
in healthy volunteers, with the peak plasma concentration
and total exposure not deviating significantly from dose-
proportionality (Fig. 2). The average plasma concentration
of buspirone 1 h after administration was 2–3 ng mL-1 per
milligram of drug dosed. The plasma concentration of the
primary metabolite, 1-PP, was below 1 ng ml-1 at all times
for all doses of buspirone.
Safety
The most commonly reported adverse events were gastroin-
testinal disturbances, such as nausea, vomiting, flatulence
and constipation, postoperative pain and nervous system
disorders, including headache and insomnia (Table 3). There
were no significant differences between the placebo group
and any of the four buspirone dose groups. Overall, 90.7 %
of patients experienced at least one adverse event during the
study, with no significant difference in adverse event rate
between the groups. A little over one-quarter of patients
experienced adverse events considered to be at least remote-
ly related to study medication, ranging from 22.0 % (0.3 mg
buspirone) up to 33.3 % (placebo).
In the 1 mg buspirone group, the Aldrete score showed a
median decline between baseline and 1 h after surgery of 1
point. This was a significantly greater decrease than that for
placebo (P<0.01) or 3 mg buspirone (P<0.05). The median
decrease in the 0.3 mg group was also significantly greater
than that for placebo (P<0.05).
Table 2 Incidence of postoperative nausea and vomiting, nausea, vomiting and/or rescue medication use in the 24-h postoperative period
Study endpoints Placebo
(N051)
Buspirone 0.3 mg
(N050)
Buspirone 1 mg
(N049)
Buspirone 2 mg
(N052)
Buspirone 3 mg
(N055)
Postoperative period 0–24 h
PONV 25 (49.0) 29 (58.0) 20 (40.8) 30 (57.7) 28 (50.9)
Nausea 22 (43.1) 24 (48.0) 17 (34.7) 25 (48.1) 23 (41.8)
Vomiting 14 (27.5) 13 (26.0) 11 (22.4) 19 (36.5) 18 (32.7)
Rescue medication use 20 (39.2) 28 (56.0) 15 (30.6) 28 (53.8) 23 (41.8)
PONV, postoperative period 0–2 h 14 (27.5) 16 (32.0) 10 (20.4) 23 (44.2) 19 (34.6)
PONV, postoperative period 2–6 h 8 (15.7) 7 (14.0) 3 (6.1) 5 (9.6) 5 (9.1)
PONV, postoperative period 6–24 h 3 (5.9) 6 (12.0) 7 (14.3) 2 (3.9) 4 (7.3)
PONV, Postoperative nausea and vomiting (including retching)
Data are presented as the number (of patients), with the percentage in parenthesis
There were no significant differences between groups
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Discussion
Nausea and vomiting remain a significant problem in the
postoperative period. Although the design and conduct of this
study were broadly similar to those of many previous PONV
studies, the approach taken to patient selection differs from the
majority of previous studies. It has been common practice to
specify as an inclusion criterion a particular operation or class
of operations, such as, for example, abdominal hysterectomy
or open abdominal surgery. Our approach was to select
patients on the basis of empirically established PONV risk
factors [2]. The resulting placebo PONV rate was adequate to
discriminate a potentially effective treatment. However, al-
though half of the patients given placebo experienced at least
one PONV episode, in the 24-h period after their operation
there was no significant difference in the incidence of PONV
between patients given placebo and those receiving any of the
different doses of buspirone.
The negative result was a surprise, given the pharmacol-
ogy of buspirone and its convincing antiemetic efficacy
when given parenterally against various emetogens in the
dog [11], cat [12, 13] and Suncus murinus [14]. There are
several possibilities for this discordance between pre-
clinical and human data. The most obvious methodological
issues involve the dose range of buspirone and the route and
timing of administration. If the animal studies are indeed
accurate in their characterization of the antiemetic activity of
buspirone, then this discordance would suggest an inappli-
cability of the animal models of emesis to the complex
situation of PONV or perhaps a true species difference in
the physiology of emesis or the behaviour of buspirone. In
pre-clinical models, the antiemetic efficacy of an experi-
mental intervention is usually tested in animals exposed to
a single emetogenic stimulus, for example, apomorphine or
morphine. However, none of these echoes PONV, which is
clearly a multifactorial phenomenon, including patient, an-
aesthesia and surgical factors.
It seems unlikely that the study data are substantially inac-
curate. Our study had a robust design with a minimal risk of
selection or observer bias. Trial size was adequate; a negative
result by random chance is therefore unlikely. The treatment
Fig. 2 Plasma concentration of buspirone against time for the different
doses of intravenous buspirone
Table 3 Treatment-emergent adverse events (excluding nausea and vomiting) occurring in at least 3 % of the patient population
Adverse events Placebo
(N051)
Buspirone 0.3 mg
(N050)
Buspirone 1 mg
(N049)
Buspirone 2 mg
(N052)
Buspirone 3 mg
(N055)
Total
(N0257)
Procedural pain 24 (47.1) 25 (50.0) 32 (65.3) 25 (48.1) 24 (43.6) 130 (50.6)
Flatulence 5 (9.8) 7 (14.0) 7 (14.3) 7 (13.5) 4 (7.3) 30 (11.7)
Insomnia 6 (11.8) 3 (6.0) 8 (16.3) 7 (13.5) 6 (10.9) 30 (11.7)
Constipation 4 (7.8) 5 (10.0) 5 (10.2) 4 (7.7) 5 (9.1) 23 (8.9)
Hypertension 2 (3.9) 0 (0.0) 1 (2.0) 4 (7.7) 4 (7.3) 11 (4.3)
Hypokalaemia 3 (5.9) 1 (2.0) 3 (6.1) 3 (5.8) 0 (0.0) 10 (3.9)
Headache 1 (2.0) 1 (2.0) 4 (8.2) 4 (7.7) 0 (0.0) 10 (3.9)
Dizziness 1 (2.0) 1 (2.0) 2 (4.1) 3 (5.8) 2 (3.6) 9 (3.5)
Hypothermia 1 (2.0) 1 (2.0) 2 (4.1) 2 (3.8) 2 (3.6) 8 (3.1)
Data are presented as the number (of patients), with the percentage in parenthesis
There were no differences between groups (i.e. all P values >0.05)
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armswere well-balanced. Indeed, the study delivered complete-
ly consistent efficacy data across all parameters and subsets.
One explanation for the discordance may relate to the
dose range of intravenous buspirone in the trial. Extrapolat-
ing dose from animal to man is difficult. For example, the
published KI value for buspirone against D2 is some tenfold
higher in the rat [19] than in humans [20], although this does
not necessarily mean the same is true in any other small
mammal species. The pharmacokinetics and binding affinity
of buspirone for the D2 and 5HT1A receptors in the ferret
are unknown and may be very different from those in
humans. When the difference in the ratio of volume to surface
area between these species are taken into consideration, it has
been proposed that a dose of a drug in ferrets is equivalent to
5.3-fold the dose in humans [17]. However, that would as-
sume a broad similarity in terms of pharmacokinetics and
pharmacodynamics. This cannot be verified in the case of
buspirone because its pharmacokinetics and its binding affin-
ity for the D2 and 5HT1A receptors in the ferret are unknown
and may be very different from those in humans.
It may be that subcutaneous rather than intravenous ad-
ministration is required to achieve an antiemetic effect,
perhaps by reducing the ratio of peak plasma concentration
to overall exposure. We had decided to avoid dosing intra-
venous buspirone above 3 mg due to the fear of 5HT1A-
related central nervous system effects. This decision may
have prevented exploration of the effective dose range of the
agent, and in particular its effective dose as a D2 antagonist.
The complex interaction of buspirone with 5HT1A recep-
tors may also provide an explanation. Buspirone acts at two
main groups of 5HT1A receptors: pre-synaptic auto-receptors
in the dorsal raphe nucleus, inhibiting serotonin release, and
post-synaptic receptors in the cortical and limbic regions [19,
21, 22]. Because of their greater density, pre-synaptic auto-
receptors are activated at lower doses of buspirone. These
receptor populations may have opposite effects in terms of
emesis. The selective 5HT1A partial agonist tandospirone,
when given at a moderate oral dose, was found to be effective
as an antiemetic in a clinical study [4], but provoked vomiting
when given orally at high doses (100 mg kg-1 day-1) to dogs in
an acute toxicity study [23]. Peak plasma concentrations of
buspirone resulting from intravenous dosingmay have acutely
activated both pre- and post-synaptic receptor populations,
triggering pro-emetic as well as, or instead of, antiemetic
pathways. The observation that activation of 5HT1A receptors
in the prefrontal cortex of rats led to increased mesocortical
dopamine release [24] may provide a clue as to the mechanism
bywhich high concentrations of buspirone could provoke—or
at least fail to prevent—emesis.
The partial agonist behaviour of buspirone, meaning that
it exhibits both agonist and antagonist activity at the 5HT1A
receptor, may also add complexity. The agonist effect would
tend to be inversely proportional to the concentration of
serotonin present at the receptor. In a situation where there
is a high level of endogenous serotonin, such as may be the
case in a patient suffering from PONV, buspirone may act as
a relative antagonist by competing with the fully agonist
endogenous serotonin [25]. At pre-synaptic autoreceptors,
this could lead to increased serotonin release.
Finally, it is possible that the 5HT1A activity of buspironemay
have species-dependent effects. Pathways involving 5HT1A, as
well as the interaction between D2 and 5HT1A, may be substan-
tiallymore complex in humans than in other animals. Full 5HT1A
agonists, such as flesinoxan and repinotan, have been reported to
provoke nausea and vomiting in humans [26–28] but to prevent
emesis in the cat [29]. Given the heavy involvement of 5HT1A
pathways in higher cortical functions such as learning and mem-
ory [30], it does seem plausible that significant differences would
exist in such pathways between animal brains and that they are
far more developed in the human brain.
In conclusion, in this first clinical study of the perioper-
ative use of intravenous buspirone, we were unable to con-
firm a beneficial effect, within the tested dose-range, on the
prevention of PONV. The results of this study emphasise the
difficulty in extrapolating from animal models of emesis to
clinical efficacy in PONV.
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